Eyepoint Pharmaceuticals Inc Total Assets
Eyepoint Pharmaceuticals Inc total assets. Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) holds total assets worth $251.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Eyepoint Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Eyepoint Pharmaceuticals Inc (2000–2024)
Total assets of Eyepoint Pharmaceuticals Inc from 2000 to 2024. This chart illustrates how Eyepoint Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Eyepoint Pharmaceuticals Inc for real-time trading data and today's change.
Eyepoint Pharmaceuticals Inc - Asset Composition Analysis
Eyepoint Pharmaceuticals Inc Total Assets Breakdown (December 2024)
Eyepoint Pharmaceuticals Inc total assets breakdown as of December 2024. Eyepoint Pharmaceuticals Inc's total assets of $251.69 Million consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.8% |
| Accounts Receivable | $607.00K | 0.2% |
| Inventory | $2.31 Million | 0.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Eyepoint Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EYPT working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eyepoint Pharmaceuticals Inc's current assets represent 91.6% of total assets in 2024, an increase from 36.7% in 2000.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, down from 34.8% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 55.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 0.6% of total assets.
Eyepoint Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eyepoint Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Eyepoint Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.18 | 5.50 | 4.24 |
| Quick Ratio | 7.11 | 5.45 | 3.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $186.01 Million | $219.75 Million | $48.23 Million |
Eyepoint Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eyepoint Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.59 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 17.8% |
| Total Assets | $418.46 Million |
| Market Capitalization | $32.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Eyepoint Pharmaceuticals Inc's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Eyepoint Pharmaceuticals Inc's assets grew by 17.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eyepoint Pharmaceuticals Inc (2000–2024)
The table below shows the annual total assets of Eyepoint Pharmaceuticals Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $418.46 Million | +17.82% |
| 2023-12-31 | $355.18 Million | +96.93% |
| 2022-12-31 | $180.36 Million | -31.52% |
| 2021-12-31 | $263.37 Million | +187.16% |
| 2020-12-31 | $91.72 Million | +25.69% |
| 2019-12-31 | $72.97 Million | +1.82% |
| 2018-12-31 | $71.67 Million | +283.73% |
| 2017-12-31 | $18.68 Million | -40.93% |
| 2016-12-31 | $31.62 Million | -2.31% |
| 2015-12-31 | $32.37 Million | +42.77% |
| 2014-12-31 | $22.67 Million | +39.52% |
| 2013-12-31 | $16.25 Million | -21.11% |
| 2012-12-31 | $20.60 Million | -56.28% |
| 2011-12-31 | $47.11 Million | +9.53% |
| 2010-12-31 | $43.01 Million | +15.93% |
| 2009-12-31 | $37.10 Million | -5.42% |
| 2008-12-31 | $39.23 Million | -54.45% |
| 2007-12-31 | $86.12 Million | -11.76% |
| 2006-12-31 | $97.60 Million | +56.67% |
| 2005-12-31 | $62.30 Million | 0.00% |
| 2004-12-31 | $62.30 Million | +122.09% |
| 2003-12-31 | $28.05 Million | +481.92% |
| 2002-12-31 | $4.82 Million | +2.15% |
| 2000-12-31 | $4.72 Million | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more